Literature DB >> 2937482

Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration.

A Ohlsson, J E Lindgren, S Andersson, S Agurell, H Gillespie, L E Hollister.   

Abstract

The disposition of deuterium-labelled cannabidiol, 2H2-CBD, was studied in five young men who were marihuana smokers. The pattern of use ranged from infrequent to frequent use of the drug. Plasma concentrations, determined by mass fragmentography, were followed for 72 h after both intravenous administration of 20 mg 2H2-CBD and smoking of an estimated amount of 18.8-19.4 mg 2H2-CBD. Systemic availability after smoking was determined by comparing the areas under the plasma concentration versus time curves for the two treatments and was found to be 31 +/- 13%. A four-fold difference in the availability of the compound was noted for the five subjects. Based on the area under the curve and the dose after intravenous administration, a plasma clearance of 960-1560 ml min-1 was calculated. A terminal elimination phase was not reached at 72 h, but the kinetic parameters were estimated from the 72 h beta-elimination. A half-life of 31 +/- 4 h after smoking and 24 +/- 6 h after injection was estimated as well as a distribution volume of 2520 +/- 470 l (32.7 +/- 8.61 kg-1).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937482     DOI: 10.1002/bms.1200130206

Source DB:  PubMed          Journal:  Biomed Environ Mass Spectrom        ISSN: 0887-6134


  47 in total

1.  Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Authors:  Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-11-15       Impact factor: 8.327

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder.

Authors:  Daniel J Liput; Dana C Hammell; Audra L Stinchcomb; Kimberly Nixon
Journal:  Pharmacol Biochem Behav       Date:  2013-09-05       Impact factor: 3.533

4.  Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry.

Authors:  David M Andrenyak; David E Moody; Matthew H Slawson; Daniel S O'Leary; Margaret Haney
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

Review 5.  Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

Authors:  Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

6.  Barriers to the wider adoption of medicinal Cannabis.

Authors:  Stephen Ph Alexander
Journal:  Br J Pain       Date:  2020-05-29

7.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Authors:  S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

8.  Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.

Authors:  Atheer Zgair; Jonathan Cm Wong; Jong Bong Lee; Jatin Mistry; Olena Sivak; Kishor M Wasan; Ivo M Hennig; David A Barrett; Cris S Constantinescu; Peter M Fischer; Pavel Gershkovich
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

9.  Context-sensitive decrement times for inhaled anesthetics in obese patients explored with Gas Man®.

Authors:  Jonas Weber; Johannes Schmidt; Steffen Wirth; Stefan Schumann; James H Philip; Leopold H J Eberhart
Journal:  J Clin Monit Comput       Date:  2020-02-17       Impact factor: 2.502

10.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.